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The mechanisms underlying the maintenance and dysfunction of exhausted pDCs during chronic viral infection are unclear. Macal and Jo et al. find that exhausted pDCs are maintained by IFN-I and TLR7 signaling via multiple mechanisms, including inhibition of bone marrow pDC generation, sustained proliferation of exhausted pDCs, and promotion of pDC functional loss, the latter of which leads to impaired host defense to secondary infection.
INTRODUCTION
Chronic infections, including human immunodeficiency virus (HIV) infection, mycobacterium tuberculosis, and malaria, represent a major health burden. Immunosuppression, a hallmark of chronic infections, limits the immune response to the ongoing pathogen as well as unrelated microbes, cancer, and vaccination (Stelekati and Wherry, 2012; Virgin et al., 2009; Zuniga et al., 2015) . Although detrimental for host defense, such immunosuppression can be seen as a host adaptation that enables long-term survival and coexistence with the pathogen. Indeed, hosts with genetic ablation of core immunosuppressors often die after infection (despite having enhanced microbial control) (Virgin et al., 2009; Zuniga et al., 2015) . Nevertheless, shortterm therapeutic relief of some immunosuppressors during infection can be tolerated and beneficial in clearing the persistent pathogen and/or secondary insults (Attanasio and Wherry, 2016; Zuniga et al., 2015) . Although host adaptations have been extensively studied in T and B cells, which undergo functional exhaustion during chronic infections and cancer (Attanasio and Wherry, 2016; Moir and Fauci, 2014) , much less is known about the mechanisms mediating long-term adaptations in the innate immune system. In particular, it is unclear how innate immune exhaustion can be sustained long-term given that innate cells are generally short lived.
Type I interferons (IFNs-I) provide critical resistance to infections and tumors by limiting the spread of the infectious agent or malignant transformation and by activating multiple innate and adaptive immune cells (García-Sastre and Biron, 2006; McNab et al., 2015; Zitvogel et al., 2015) . Plasmacytoid dendritic cells (pDCs), the most potent IFN-I-producing cells, rapidly respond to murine and human persistent viruses by releasing copious amounts of these cytokines (Borrow, 2011; Lee et al., 2009; Reizis et al., 2011; Swiecki and Colonna, 2015; Zuniga et al., 2015) . Consistently, mice deficient in pDCs fail to control several acute and chronic viral infections (Reizis et al., 2011; Swiecki and Colonna, 2015) . We and others, however, have reported at later stages of chronic infections the presence of sustained hypo-functionality of pDCs (Duan et al., 2004; Feldman et al., 2001; Kanto et al., 2004; Lee et al., 2009; Zuniga et al., 2008) ; hereafter referred to as pDC exhaustion. These exhausted pDCs fail to produce IFN-I in response to the ongoing infection, synthetic toll-like receptor (TLR) ligands, and/or unrelated viruses, and this functional exhaustion is accompanied by compromised innate responses and control of secondary opportunistic infections (Feldman et al., 2001; Lee et al., 2009; Zuniga et al., 2008) . Furthermore, although systemic IFN-I is often elevated early after chronic infection, it is rapidly and profoundly attenuated afterward, and only low amounts of IFN-I and/or an ''interferon signature'' persists in tissues (Borrow, 2011; Bruel et al., 2014; Ng et al., 2016; Snell and Brooks, 2015; Stacey et al., 2009 , Zuniga et al., 2015 . Prophylactic pDC stimulation, delayed IFN-I downregulation, or IFN-I inoculation before or after 
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infection with a chronic virus enhances T cell responses and host resistance, indicating that the rapid and profound IFN-I attenuation during chronic viral infection promotes T cell exhaustion and viral persistence (Blasius et al., 2012; Lee et al., 2009; Sandler et al., 2014; Vanderford et al., 2012; Wang et al., 2012) . IFN-I exhaustion has also been reported in tumor-associated pDCs, and targeting of pDCs to restore their IFN-I production capacity has been proposed as a means of overcoming cancer immune suppression (Hartmann et al., 2003; Labidi-Galy et al., 2011; Sisirak et al., 2012) . However, the mechanisms maintaining the numbers of exhausted pDCs and their functional loss in chronic settings remain unknown.
In this study, we used persistent lymphocytic choriomeningitis virus (LCMV) clone 13 (Cl13) infection in its natural murine host and found that long-term maintenance of exhausted pDCs involved both compromised numbers and pDC generative capacity of bone marrow (BM) progenitors as well as self-renewal of exhausted pDCs in the periphery. Whereas both IFN-I and TLR7 signaling contributed to peripheral pDC proliferation, only IFN-I was responsible for reduced pDC progenitors. On the other hand, TLR7 mediated pDC functional impairment, compromising IFN-I elevation and resistance upon secondary infection. Together, these findings provide an anatomical, cellular, and molecular explanation for pDC exhaustion during chronic inflammation.
RESULTS

Both Spleen and BM pDCs Exhibit Sustained Functional Exhaustion during Chronic LCMV Infection
We previously reported that spleen pDCs, identified by coexpression of B220 and CD11c, exhibited long-lasting functional exhaustion during chronic LCMV infection (Zuniga et al., 2008) . To further validate these findings and investigate whether pDC exhaustion also occurred in the BM, we adopted a more rigorous pDC gating strategy that included the pDC marker BST2 (Asselin-Paturel et al., 2003; Blasius et al., 2006) (Figure 1A ). Consistent with our previous report (Zuniga et al., 2008) , splenic pDCs from both LCMV Armstrong (ARM)-and Cl13-infected mice showed lower IFN-I production in response to a TLR9 agonist CpG than did uninfected controls at days 5 and 10 post-infection (p.i.), and this reduction was sustained only in pDCs from Cl13-infected mice at day 30 p.i. (Figure 1B ). Sustained suppression of IFN-I production was also observed in BM pDCs from C113-infected (but not ARM-infected) mice (Figure 1C) . Furthermore, the more rigorous pDC gate revealed reduced tumor necrosis factor (TNF)-a production by splenic and BM pDCs isolated at day 5 or 10 after either ARM or Cl13 infection ( Figure S1A ). This defect was, however, fully or partially recovered 30 days after both infections. Finally, CD86 expression was upregulated upon CpG stimulation in splenic and BM pDCs from ARM-or Cl13-infected mice ( Figure S1B ), indicating that exhausted pDCs were still responsive to TLR stimulation. These data indicated that both splenic and BM pDCs acquired functional defects upon infection with either acute or persistent LCMV. Although pDCs from acutely infected mice recovered a few weeks after infection, pDC exhaustion was sustained in the chronic setting.
BM pDC Progenitor Numbers Are Reduced Long-Term and Fail to Generate Functional pDCs after Chronic LCMV Infection Given that pDCs are short lived (Liu et al., 2007; Zhan et al., 2016) , we reasoned that sustained pDC exhaustion during chronic LCMV infection (Zuniga et al., 2008) might involve long-term adaptations occurring at the level of pDC progenitors. To evaluate this possibility, we first assessed the effect of acute and chronic LCMV infection on the numbers of BM progenitors that have been reported to generate pDCs: common lymphoid progenitors (CLPs), common DC progenitors (CDPs), and CD115
À CDP-like pDC progenitors (reviewed in Swiecki and Colonna, 2015) . As shown in Figure 1D , the percentage and number of CLPs were reduced by day 10 p.i., and by day 30 p.i., numbers remained significantly decreased only in Cl13-infected mice. The numbers of CDPs and CD115 À progenitors tended to increase at day 5 p.i. but were also reduced by day 10 p.i. in both ARM-and Cl13-infected mice compared to uninfected controls. At day 30 p.i., CD115 À progenitor numbers were restored, whereas CDP numbers remained reduced in Cl13-infected (but not ARM-infected) mice. Similarly, the numbers of common myeloid progenitors (CMPs), which can give rise to pDCs via CDPs (Sathe et al., 2013) , were also reduced in both ARM-and Cl13-infected mice at day 10 p.i., whereas such a reduction was sustained only in the latter group at day 30 p.i. (Figures S2A and S2B ). In contrast, the numbers of granulocyte-monocyte progenitors (GMPs) were not significantly reduced in acute or chronic LCMV infections at any of the time points studied ( Figures S2A and S2C Figure 1E ), we observed a decrease in the number of donor-derived pDCs when recipients had received BM progenitors from Cl13-infected versus uninfected donors ( Figures S2D  and S2E ).
To further understand BM progenitor adaptations after infection, we evaluated the function of pDCs derived from BM progenitors. pDCs from Flt3L cultures of BM from ARM-or Cl13-infected mice at days 5 and/or 10 p.i. showed ablated IFN-I production in response to TLR stimulation ( Figure 1F ). However, compromised BM capacity to generate functional pDCs was sustained in Cl13-infected mice by day 30 p.i., whereas BM-derived pDCs from ARM-infected mice exhibited restored IFN-I production upon CpG-A stimulation ( Figure 1F ), although we continued observing reduced response to CpG-B at day 30 after ARM infection (not shown).
Together, these results indicated that both acute and chronic infections compromised long-term the ability of BM to generate pDCs. In addition, our results showed sustained ablation of CLPs, CMPs, and CDPs and lasting functional exhaustion of BM-derived pDCs in chronically infected hosts.
Splenic and BM pDCs Proliferate and Expand CD4
Subsets throughout Chronic LCMV Infection We next investigated whether loss of pDC progenitors and diminished BM pDC generation affected pDC numbers. In agreement with apoptosis of pDCs early during infection (Swiecki et al., 2011) and the long-term compromise capacity of BM to generate pDCs after ARM and Cl13 infections ( Figure 1E ), spleen pDC numbers were significantly reduced at days 5 and 30 after both infections (Figure 2A and Zuniga et al., 2008) . However, numbers of BM pDCs were mostly unchanged at all the time points studied ( Figure S3A ), and spleen pDC numbers were restored or even enhanced at day 10 ( Figure 2A ) after ARM and Cl13 infection. To determine how pDC numbers were maintained despite the reduced generation of pDCs from BM, we investigated the presence of proliferating cells within spleen and BM pDCs over the course of ARM and Cl13 infections. Consistent with previous studies (Liu et al., 2007; Zhan et al., 2016) , we detected < 2% proliferating pDCs in the spleen of uninfected mice, as indicated by the nuclear antigen Ki67 expression and in vivo bromodeoxyuridine (BrdU) incorporation ( Figures 2B and 2C ). In contrast, we observed a substantial number of proliferating pDCs in spleen (Figures 2B and 2C) and BM ( Figure S3B and S3C) from both ARM and Cl13 infected mice at day 5 p.i., and this was sustained at days 10 and 30 after chronic (but not acute) LCMV infection. BrdU was also incorporated by pDCs from Cl13-infected, but not uninfected, mice when splenocytes were cultured ex vivo, further supporting the proliferative capacity of splenic pDCs during Cl13 infection ( Figure S3D ).
Proliferating CD4 À CCR9 À and CD4 À CCR9 + pDC subsets have been reported in the BM of uninfected mice as immature pDCs or immediate precursors of CD4 + CCR9 + pDCs (Schlitzer et al., 2012; Schlitzer et al., 2011; Zhan et al., 2016) . On the other hand, almost all splenic pDCs express chemokine receptor CCR9 and do not proliferate under steady-state conditions (Schlitzer et al., 2012; Schlitzer et al., 2011; Zhan et al., 2016) . In contrast to almost undetectable CD4 À CCR9 À pDCs in uninfected mice, an increased number of CD4 À CCR9 À cells were detected within splenic pDCs from both ARM-and Cl13-infected mice at day 5 p.i., and this phenotype was sustained at days 10 and 30 after chronic (but not acute) infection ( Figure 2D ). Moreover, whereas none of the spleen pDC subsets proliferated in uninfected mice, both CD4 À CCR9 + and CD4
subsets contained a significant proportion of proliferating cells at day 5 after either ARM or Cl13 infection, and this was only sustained in Cl13 infection at days 10 and 30 p.i. (Figure 2E ). A similar pattern was observed in the BM at days 5, 10, and 30 after ARM and Cl13 infection (Figures S3E and S3F) and in both compartments the CD4 À CCR9 À pDC subset showed the highest proliferation in ARM-infected mice at day 5 p.i. and throughout Cl13 infection ( Figure 2E and Figure S3F ). Altogether, these data indicate that while BM pDC generation was compromised, CD4 À subsets within differentiated BM and spleen pDCs significantly expanded to replenish functionally compromised pDCs early after acute and chronic LCMV infections, and this was sustained long-term in the chronic infection.
E2-2, SPIB, and BCL11A Are Downregulated in pDCs and Their Progenitors from LCMV Cl13-Infected Mice as Well as in pDCs from HIV-Infected Patients
Given that the aforementioned phenotypes in BM progenitors and differentiated pDCs were all present at day 9 after Cl13 infection ( Figures 1 and 2 ), we focused on this time point and infection model to characterize, at the transcriptional level, their adaptations and the mechanisms involved. Because the class I helix-loop-helix TF E2-2 is a master regulator of pDC development, lineage commitment, and function (Cisse et al., 2008) , we first compared E2-2 expression in BM progenitors and pDCs from uninfected and Cl13-infected mice. We observed a significant downregulation in the amount of E2-2 (encoded by Tcf4) transcript in FACS-purified BM progenitors and splenic pDCs isolated at day 9 p.i. from Cl13-infected versus uninfected (legend continued on next page) mice ( Figures 3A and 3B ). The downregulation of Tcf4 transcripts in Cl13-infected mice appeared to be of functional significance because transcripts of downstream target TFs SPIB and BCL11A, which are also important in pDC development and/or function (Cisse et al., 2008; Murphy et al., 2016; Sasaki et al., 2012) , were similarly reduced in both BM progenitors and splenic pDCs from Cl13-infected versus uninfected mice (Figures 3A and 3B) , although Bcl11a reduction in splenic pDCs only reached significance in two out of four independent experiments (not shown). Furthermore, pDCs derived from BM of Cl13-infected mice also exhibited a significant decrease in the number of transcripts of Tcf4, Spib, and Bcl11a ( Figure 3C ). Finally, to investigate whether such TF downregulation extended to human chronic infections, we purified pDCs from HIV-infected patients and compared them to pDCs from HIV-negative controls (Table S1 ). pDC purity ranged from 77%-99% and was not different between groups ( Figure S4 ). TCF4 expression was lower in viremic patients ( Figure 3D ), in whom pDC IFN-I production capacity is significantly reduced (Feldman et al., 2001 ) with respect to that in healthy controls. Similarly, the amounts of SPIB and BCL11A were significantly lower in viremic patients than in healthy controls (Figures 3E and 3F) .
Altogether, these results demonstrated downregulation of Tcf4 and target TFs Spib and Bcl11a in BM progenitors and pDCs from chronically infected mice, and this phenotype appeared to be extendible to pDCs from HIV-viremic patients.
IFNAR Signaling Reduces pDC Progenitor Numbers, Their E2-2 Expression, and BM pDC Generation during Chronic LCMV Infection Next, we investigated the mechanisms underlying the numerical and developmental adaptations in BM pDC progenitors. Previous studies demonstrated that IFN-I inhibited development of conventional dendritic cells during chronic LCMV infection (Hahm et al., 2005; Sevilla et al., 2004) , whereas recombinant IFN-a treatment enhanced BM pDC generation in vitro and in vivo (Li et al., 2011) . To test whether IFN-I induced in the context of Cl13 infection modulated BM pDC progenitors, we treated mice with anti-IFNAR neutralizing (n) Ab before and throughout the infection and monitored the number of BM progenitors and their potential to generate pDCs at day 9 p.i. We observed a restored or enhanced number of BM pDC progenitors in Cl13-infected mice treated with anti-IFNAR nAb in comparison to the isotype-treated group ( Figure 4A ). Furthermore, significantly increased numbers of pDCs were generated in BM-Flt3L cultures from Cl13-infected mice that received anti-IFNAR nAb (Figure 4B) . Consistently, Tcf4 expression was restored in pooled BM progenitors from anti-IFNAR nAb-treated Cl13-infected mice ( Figure 4C ). To investigate whether IFNAR signaling regulated BM pDC progenitors in a cell-intrinsic manner, we next analyzed WT:Ifnar1 À/À mixed-BM chimeras after Cl13 infection.
In these chimeras, we observed a slight increase in the Ifnar1 À/À (CD45.2 + ) compared to the WT (CD45.1 + ) BM pDC progenitors ( Figure 4D ), suggesting that IFN-I regulation of BM progenitors was partly cell intrinsic. In contrast, no difference was detected in Tcf4 expression in BM progenitors from WT versus Ifnar1 À/À compartments ( Figure 4E ), indicating that IFN-I also regulated BM progenitors in a cell-extrinsic manner.
Altogether, these results demonstrated that IFN-I regulated BM pDC progenitors via cell-intrinsic and -extrinsic pathways and contributed to the numerical reduction of BM progenitors, their diminished E2-2 expression, and their limited capacity to generate pDCs.
IFNAR Signaling Promotes Splenic pDC Proliferation and Expansion of CD4
-pDC Subsets during Chronic LCMV Infection IFN-I signaling has been shown to induce pDC apoptosis after viral infections (Swiecki et al., 2011) . Thus, we reasoned that by preventing pDC apoptosis and restoring BM pDC generation, IFNAR blockade should increase the number of pDCs in periphery. However, LCMV Cl13-infected mice that received anti-IFNAR nAb exhibited lower numbers of splenic pDCs than their isotype-treated counterparts at day 9 p.i. (Figure 5A ). Figure 5D ). To investigate whether the IFN-I induction of pDC proliferation was cell intrinsic, we again analyzed WT:Ifnar1
À/À mixed-BM chimeras. We observed that Ki67 expression and in vivo BrdU incorporation were significantly reduced in Ifnar1
versus WT pDCs from Cl13-infected chimeras ( Figure 5E and 5F), indicating that IFN-I promoted pDC proliferation in a cellintrinsic manner. These data demonstrated that IFN-I induced the expansion of highly proliferative pDC subsets and promoted self-renewal of the exhausted pDC pool.
TLR7 Signaling Induces pDC Proliferation and Suppresses Their IFN-I Production after Chronic LCMV Infection
We next investigated the effect of IFN-I on the pDC functional loss during chronic LCMV infection. We observed that both BM-derived and splenic pDCs from Cl13-infected mice treated with anti-IFNAR nAb or isotype control showed similarly impaired IFN-I production after ex vivo TLR stimulation ( Figures  S5A and S5B ). These data suggested that the loss of pDC IFN-I production capacity occurred via an IFNAR-independent pathway. Given that arenavirus nucleoprotein (NP) can suppress IFN-I induction (Martínez-Sobrido et al., 2006) and that pDCs are productively infected by LCMV Cl13 (Macal et al., 2012) , we See also Figure S4 and Table S1 .
explored the possibility that the suppression of pDC IFN-I production could be explained by overwhelming viral dissemination and NP expression in pDCs. Flow-cytometric analysis of LCMV NP, however, demonstrated that the majority of pDCs did not express detectable NP at day 9 after Cl13 infection ( Figure S5C ), suggesting that loss of pDC IFN-I production capacity could be, at least in part, a consequence of cellular adaptations to chronic viral infection and could not be fully explained by anti-IFN-I effects of viral products in infected pDCs. Considering that T cell exhaustion in chronic infection is driven, in great part, by persistent TCR stimulation (Attanasio and Wherry, 2016) and that uninfected pDCs can sense LCMV via TLR7 (Macal et al., 2012) , we hypothesized that persistent TLR7 stimulation could contribute to hypo-functionality of pDCs. We first evaluated the numbers of pDC progenitors and their developmental potential, but we did not detect any difference between Cl13-infected WT and Tlr7 À/À mice ( Figures S6A and S6B ). Next, we analyzed spleen pDCs from WT and Tlr7 À/À mice at day 9 after Cl13 infection. As we described at day 1 p.i. (Macal et al., 2012) , expression of maturation markers was reduced in pDCs from Tlr7 À/À versus WT mice ( Figures S6C and S6D ), whereas pDC numbers remained unchanged ( Figure S6E ). This result indicated that TLR7 signaling continued exerting a positive effect on pDC maturation at later stages of infection. However, although pDCs from Cl13-infected WT mice were unable to produce IFN-I in To discern whether TLR7 signaling induced pDC hypo-responsiveness in a cell-intrinsic manner, we generated WT:Tlr7 À/À mixed-BM chimeras and infected them with LCMV Cl13. Again, we observed lower expression of CD86 and MHCII in Tlr7 À/À than in WT pDCs ( Figures 6B and 6C) , indicating that the positive effects of TLR7 signaling on pDC maturation were cell intrinsic. Tlr7 À/À splenic pDCs also produced significant amounts of IFN-I ( Figure 6D ) and exhibited significant Tnfa expression ( Figure S6G ) in response to ex vivo CpG stimulation, whereas their WT counterparts remained exhausted ( Figure 6D and Figure S6G) . Such an increased pDC function in Tlr7 À/À pDCs was again observed despite increased LCMV gp transcript amounts in Tlr7 À/À versus WT pDCs from Cl13-infected chimeric mice (Figure 6E) . Furthermore, pDC functional restoration coincided with an enhanced amount of Tcf4 in splenic Tlr7 À/À versus WT pDCs ( Figure 6F ), indicating that cell-intrinsic TLR7 signaling was at least partly responsible for the decreased E2-2 amounts in splenic pDCs. We next evaluated pDC proliferation in WT:Tlr7 À/ À mixed-BM chimeras upon Cl13 infection. We observed that both Ki67 expression and in vivo BrdU incorporation were significantly lower in pDCs from Tlr7 À/À compartments than in those from WT compartments ( Figures 6G and 6H ), indicating that direct TLR7 signaling also contributed to pDC proliferation after chronic LCMV infection. Overall, our results indicated that the same TLR7 signaling that induces pDC maturation and IFN-I production at day 1 after LCMV Cl13 infection (Macal et al., 2012) continued to positively regulate pDC maturation and viral control, but instead of promoting IFN-I induction, this signaling promoted functional loss and self-renewal of exhausted pDCs at later stages of infection.
TLR7 Signaling Compromises IFN-I Production and Pathogen Control upon a Secondary Infection
We have previously reported that pDC IFN-I suppression during chronic viral infection coincided with enhanced susceptibility to secondary infections (Zuniga et al., 2008) . To get more insight on the biological relevance of TLR7-mediated pDC exhaustion in the context of a secondary infection, we challenged WT and Tlr7 À/À Cl13-infected mice with MCMV. At the infection dose used in this study, the role of pDCs in promoting MCMV control is well established (Dalod et al., 2003; Krug et al., 2004; Swiecki et al., 2010) . We observed that pDC numbers were lower in LCMV-MCMV co-infection than in MCMV single infection, but this result was not altered by the absence of TLR7 signaling (Figure S7) . However, in contrast to WT mice, Cl13-infected Tlr7
Figure 7. TLR7 Enhances Susceptibility to Secondary Infection during Chronic LCMV Infection
Uninfected and LCMV Cl13-infected WT and Tlr7 À/À mice were infected with MCMV at day 20 p.i. 36 hr after MCMV infection, serum IFN-I activity was quantified (A), and FACS-purified splenic pDCs were evaluated for Ifna (B) and Ifnb (C) transcripts relative to Gapdh. MCMV titers in the liver were determined 3.5 days after MCMV infection (D). Dotted line represents the limit of detection. Bars depict means ± SEM. Symbols represent individual mice. Data are representative of two or three independent experiments with three to five mice/group. **p < 0.01, ***p < 0.001 (two-way Anova). See also Figure S7 .
mice were able to produce systemic IFN-I in response to secondary MCMV infection, albeit to a lesser extent than mice receiving MCMV alone ( Figure 7A ).
Consistently, FACS-purified splenic pDCs isolated from Tlr7
À/À (but not WT) Cl13-infected mice exhibited significant Ifna and Ifnb expression at 36 hr after MCMV infection ( Figures 7B and 7C ), indicating that, in the absence of TLR7 signaling, pDCs are at least partially capable of responding to the secondary viral infection. MCMV viral clearance is impaired in LCMV co-infected mice ( Figure 7D and Zuniga et al., 2008) , and the absence of TLR7 partially restored this impaired control, with MCMV titers $10 times lower in Tlr7 À/À than in WT co-infected mice ( Figure 7D ), consistent with higher systemic IFN-I and pDC functional restoration in the Tlr7 À/À dually-infected group. Together, these results indicate that TLR7 signaling during LCMV Cl13 infection compromised pDC IFN-I response to an unrelated pathogen, and that this effect most likely contributed to the hosts' limited capacity to contain this unrelated infection.
DISCUSSION
Production of soluble mediators, including IFN-I, after recognition of conserved pathogen-associated molecular patterns (PAMPs) represents a cornerstone of innate immune responses (Iwasaki and Medzhitov, 2015) . Therefore, sustained silencing of systemic IFN-I (in the face of copious amounts of PAMPs) during chronic viral infections (Borrow, 2011; Bruel et al., 2014; Stacey et al., 2009; Zuniga et al., 2008; Zuniga et al., 2015) is highly intriguing and suggests long-term innate adaptations to the chronic infectious environment, although the underlying mechanisms remain to be determined. Here we studied pDC adaptation to chronic infection and revealed that the maintenance of an exhausted pDC pool was achieved via two mechanisms: IFN-I signaling limited de novo pDC generation from BM progenitors while promoting (together with TLR7) self-renewal of exhausted pDCs in the periphery, whereas TLR7 signaling curtailed pDC IFN-I production capacity. All progenitor and pDC adaptations that we observed during chronic LCMV infection were also detected early after acute LCMV infection, supporting the view that they represent general responses to microbial exposure. However, most of these adaptations were sustained long term only during chronic LCMV infection, suggesting that a persisting infectious environment is necessary to perpetuate them. It is conceivable that downregulation of E2-2 and its targets SPIB and BCL11A, which are critical for pDC development, lineage commitment, and/or function (Cisse et al., 2008; Ghosh et al., 2010; Murphy et al., 2016; Sasaki et al., 2012) , contributed to the limited generation of functional pDCs from BM and/or the functional loss of exhausted pDCs during chronic LCMV infection in mice, and this might extend to HIV-infected patients. Similarly, as we observed in mice chronically infected with LCMV, it is possible that an initial IFN-I peak and/or a persistently low IFN-I signature (Borrow, 2011; Feldman et al., 2001; Snell and Brooks, 2015; Stacey et al., 2009; Zuniga et al., 2015) could suppress BM pDC generation in chronically infected patients, explaining the decreased numbers of circulating pDCs (Duan et al., 2004; Feldman et al., 2001; Kanto et al., 2004) . Although this might appear at odds with a previous report showing that (under non-infectious conditions) recombinant IFN-a enhances BM pDC generation (Li et al., 2011) , it is likely that factors in the infectious environment could modulate the cell-intrinsic or -extrinsic effects of IFN-I signaling on BM progenitors.
Increased BrdU incorporation and Ki67 expression in pDCs have been shown in SIV-infected macaques (Brown et al., 2009; Bruel et al., 2014; Li et al., 2015) . Ex vivo BrdU incorporation was, however, not detected in the original SIV infection study (Brown et al., 2009 ), leading to the interpretation that Ki67 + or BrdU + pDCs represent cells recently egressed from BM (Brown et al., 2009; Bruel et al., 2014) . In our study, ex vivo BrdU was incorporated by splenic pDCs from chronically infected mice, supporting peripheral pDC proliferation. Thus, we propose that initial TLR7 signaling and IFN-I elevation might induce expansion of CD4 À pDC subsets after both acute and chronic LCMV infection, whereas continuous TLR stimulation and low IFN-I amounts perpetuate peripheral self-renewal of exhausted pDCs during chronic infection. The initial, more robust, pDC proliferation could allow restoration of pDC numbers after their initial ablation (Swiecki et al., 2011) despite limited BM pDC generation and could result in the pDC accumulation that we observed in lymphoid organs at day 10 after LCMV infection and that others have reported in HIV-infected patients (Dillon et al., 2008; Foussat et al., 2001; Nascimbeni et al., 2009; Tilton et al., 2008) . pDC proliferation was, however, subsequently attenuated, explaining the decline in pDC numbers at later stages after LCMV, HIV, and SIV infections (Biancotto et al., 2007; Brown et al., 2009; Zuniga et al., 2008) . We also showed that pDC functional loss involved TLR7 signaling, which coincidentally downregulated E2-2. pDC exhaustion due to sustained TLR stimulation could be particularly relevant for persistent viral infections but might also extend to tumor-associated pDCs (Hartmann et al., 2003; Labidi-Galy et al., 2011; Sisirak et al., 2012) , which might receive continuous TLR signaling by nucleic acids from dying cells (Fuertes et al., 2013) . Our results are in line with in vitro studies showing that CpG stimulation downregulates E2-2 expression in murine pDCs and a human pDC cell line (Cisse et al., 2008) and that pDCs are unable to induce secondary responses after TLR stimulation (Ito et al., 2006) . However, TLR7 deficiency only partially protected pDC IFN-I production capacity, indicating that other mechanisms contributed to pDC exhaustion, as previously proposed (Schwartz et al., 2017; Vincent et al., 2011; Zuniga et al., 2015) . Together with these reports, our data highlight involvement of host innate regulatory mechanism analogous to T and B cell exhaustion in IFN-I suppression during chronic infection. Finally, our findings suggest that prolonged therapeutic administration of TLR ligands (Iribarren et al., 2015) could cause pDC exhaustion and enhanced susceptibility to secondary infections.
It is tempting to speculate that the evolutionary driver of the rapidly triggered pDC exhaustion in both acute and chronic infections might have been the need for limiting IFN-I-induced immunopathology, which can be lethal after some infections (McNab et al., 2015; Ng et al., 2016) . Furthermore, maintenance of an exhausted pDC pool via local self-renewal could provide an infected host with greater plasticity to tailor pDC functions according to pathogen load or other cues in the nearby environment. Sustained IFN-I exhaustion comes, however, with a cost for the infected host, who becomes compromised in the ability to mount optimal innate responses and control certain secondary infections and tumors (Feldman et al., 2001; Jarrett, 2006; Kohler et al., 1990; Zuniga et al., 2008) . Nonetheless, increased IFN-I amounts and enhanced resistance to a secondary pathogen upon the prevention of pDC exhaustion in our study opens the possibility that combining transient recovery from innate exhaustion with existing treatments targeting adaptive immune cells could enable more effective control of chronic infections and associated opportunistic pathogens and/or tumors.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice Female C57BL/6 mice (6-8 weeks old) were purchased from The Jackson Laboratory. Tlr7 À/À mice were obtained from Dr. Maripat
Corr (University of California, San Diego) (Lund et al., 2004) . Ifnar1 À/À mice were obtained from Dr. Charles Surh (La Jolla Institute for Allergy and Immunology). All mice were housed under specific-pathogen-free conditions at the University of California, San Diego.
Mice were bred and maintained in a closed breeding facility and mouse handling and experiments conformed to the requirements of the National Institute of Health and the Institutional Animal Care and Use Guidelines of UC San Diego. Unless stated otherwise, experiments were initiated in mice (female and male) at 7-12 weeks of age.
Virus Strains
Mice were infected with 2 3 10 6 plaque-forming units (pfu) of LCMV Arm (ARM) or LCMV clone 13 (Cl13) intravenously (i.v.) via tail vein. Viruses were propagated on BHK cells and quantified by plaque assay performed on Vero cells (Ahmed et al., 1984) . In brief, Vero cell monolayers were infected with 500 mL of serially diluted viral stock and incubated for 60 minutes at 37 C in 5% CO 2 with gentle shaking every 15 minutes. Agarose overlay was added to infected cells and placed in incubator for 6 days at 37 C in 5% CO 2 . Cells were fixed with formaldehyde and stained with crystal violet for 5 minutes at room temperature and plaques were counted.
Mice were infected with 1 3 10 4 PFU of MCMV Smith intraperitoneally (i.p.). Viruses were propagated in vivo in 3-week-old BALB/c mice infected with 1 3 10 4 pfu by an i.p. route and quantified by plaque assay as described below (Tabeta et al., 2004) .
Human Samples
All human subject studies were approved by the Institutional Review Board (IRB) at Rutgers, the State University of New Jersey, New Jersey Medical School. Blood samples from HIV-negative and HIV-infected volunteers were obtained with consent according to institutional guidelines and the Declaration of Helsinki. Age and sex of the subjects are provided in table S1 of the manuscript.
Cell Lines ISRE-L929 reporter cells (male origin, provided by Dr. Bruce Beutler, University of Texas South Western Medical Center) and NIH 3T3 cells (sex information not available) were cultured in DMEM containing 10% FBS, penicillin-streptomycin, and supplements of L-glutamine. 1x10 6 cells were passaged every 3-4 days. Cells were washed in PBS pH 7.4 then lifted from culture flasks with 0.05% Trypsin-EDTA. Trypsin was deactivated by addition of serum containing media.
Primary Cell Culture
BMDCs were differentiated at the concentration of 2x10 6 cells/ml for 8 days in 5ml of RPMI-1640 supplemented with 10% (vol/vol) fetal bovine serum, L-glutamine, penicillin-streptomycin, and HEPES pH 7.2) supplemented with 100ng/mL Flt3L and 50mM b-mercaptoethanol. Half of the medium was replaced after 5 days with fresh cytokines added.
METHOD DETAILS
Mouse Cell Purification Spleens were incubated with 1mg/mL collagenase D for 20 min at 37 C and passed through a 100mm strainer to achieve a single cell suspension. For purification of spleen or BM pDCs, splenocytes or BM cells were enriched with PanDC microbeads using an Automacs system (Miltenyi) or by using EasySep Mouse Streptavidin RapidSpheres Isolation Kit (StemCell Technologies, Inc.), biotinconjugated anti-Thy1.2 (53-2.1), and anti-CD19 (6D5). PanDC+ fractions or fractions unbound to streptavidin beads were stained with propidium iodide (PI) and FACS-purified using a BD ARIA II (BD Biosciences) for pDCs ( high . Purity of the cells was > 95% (data not shown).
Human pDC Purification
Peripheral blood mononuclear cells were separated from freshly collected blood using Lymphocyte Separation Media (Mediatech, Inc). pDCs were further purified by using a diamond pDC isolation kit (Miltenyi) following the manufacturer's instructions. Purity was evaluated by flow cytometry.
Flow Cytometry
The following antibodies were used to stain single cell suspensions prepared from murine BM or spleens: Thy 1.2 (53-2.1), CD19 (eBio1D3), NK 1.1 (PK136), Gr-1 (RB6-8C5), CD11c (N418), CD11b (M1/70), B220 (RA36B2), BST2 (eBio927), CD45.2 (104), CD4 (RM4-5), CD8 (53-6.7), Ter119 (TER-119), CD3 (145-2C11), CD45.1 (A20), MHC class II (I-A/I-E) (M5/114.15.2), CCR9 (eBioCW-1.2), Ki67 (SolA15), c-kit (2B8), CD115 (AFS98), Flt3 (A2F10), Streptavidin, CD127 (eBioRDR5), CD86 (GL1), CD34 (RAM34), CD16/32 (93), and CD138 (281-2). PI or Ghost dye (Tonbo Biosciences, San Diego, CA) was used to exclude dead cells. Cells were pre-incubated with CD16/CD32 Fc block (BD PharMingen) prior to surface staining. Staining for Ki67 (SolA15) was performed as directed using the Foxp3 / Transcription Factor Staining kit. To measure in vivo BrdU incorporation in pDCs, mice were injected with 2mg BrdU (Sigma Aldrich). 16 hours later, spleens were harvested and splenocytes were stained using the BrdU Flow kit (BD Biosciences) following manufacturer instructions. To measure BrdU incorporation ex vivo, splenocytes were cultured at a concentration of 2 3 10 6 cells/ml with 10mM BrdU. 7 hours later, cells were harvested and stained using the BrdU Flow kit (BD Biosciences) following manufacturer instructions. Cells were acquired with a LSRII flow cytometer (BD Biosciences) and data were analyzed using FlowJo software (Treestar, Inc.).
Cytokine Measurements
For cytokine measurement in culture supernatants, spleen or BM cells from individual mice in the same group were pooled prior to FACS purification. FACS-purified pDCs (3 3 10 4 cells/well) were incubated in 120ul RPMI-1640 supplemented with 10% (vol/vol) fetal bovine serum, L-glutamine, penicillin-streptomycin, and HEPES pH 7.2) supplemented with 50mM b-mercaptoethanol in the presence or absence of CpG-B 1668 (Integrated DNA Technologies) at 0.1mM (Flt3L culture-derived pDC) or 1mM (splenic and BM pDC) or CpG-A 1585 (InvivoGen) at 0.5uM for 6 or 15 hours at 37 C. Supernatants were collected and stored at À80 C until further analysis. IFN-I bioactivity was measured with reference to a recombinant mouse IFNb standard (Sigma-Aldrich) using ISRE-L929 reporter cells (L-929 cell line transfected with an interferon-sensitive luciferase) (Jiang et al., 2005) . IFNa and IFNb were measured by Lumikine mIFNa and Lumikine Xpress mIFNb ELISA (InvivoGen), respectively, following manufacturer instructions. TNFa was measured by Mouse TNF alpha ELISA Ready-SET-Go!Ò (eBioscience) following manufacturer instructions. Graphs depicting cytokine measurements in this paper represent individual wells of stimulation.
Quantitative Real-Time RT-PCR (qRT-PCR) Analysis
For qRT-PCR analysis, spleen or BM cells from individual mice in the same group were pooled prior to FACS purification. Total RNA was extracted using RNeasy kits (QIAGEN), digested with DNase I (RNase-free DNase set; QIAGEN) and reverse-transcribed into cDNA using Superscript III RT (Invitrogen). The expression of various genes was quantified using Fast SYBR Green Master Mix (Thermo Fisher Scientific) or TaqMan Fast Universal PCR Master Mix with probe sets from the Universal Probe Library (Roche) and a Real-Time PCR Detection System (Applied Biosystems) or CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Primers for the test genes and probe sets are listed in Table S2 . The relative transcript amounts were normalized against murine Gapdh or human GAPDH as described previously (Macal et al., 2016) . Graphs depicting qRT-PCR analysis of murine genes in this paper represent technical triplicates from one representative experiment.
In vivo IFNAR Blockade WT mice were treated with 500mg/mouse intraperitoneally (i.p.) with neutralizing antibody (nAb) to IFNAR (clone MAR1-5A3; BioXCell) or Anti-Mouse IgG1 Isotype Control (clone MOPC-21; BioXCell) on days À1 and 0 post-LCMV Cl13-infection. Mice were then treated with 250mg/mouse anti-IFNAR nAb or isotype control i.p. on days 2, 4, and 6 post-LCMV Cl13 infection as previously described (Wilson et al., 2013) . Uninfected control mice were similarly treated in parallel.
Generation of Mixed-BM Chimeras WT CD45.1 + C57BL/6 recipient mice were sub-lethally irradiated with 1000 rads and reconstituted with a 1:1 mix of BM cells from CD45.1 + WT mice and CD45.2 + Tlr7 À/À or Ifnar1 À/À mice (or CD45.2 + WT mice for WT:WT controls). 5-10x10 6 total mixed BM cells were transferred i.v. into the irradiated recipient mice, which were treated with antibiotics (Trimethoprim 8 mg/ml and Sulfamethoxazole 40 mg/ml supplied in drinking water; Akorn) for 3 weeks to prevent infection and allow immune reconstitution.
Reconstitution was analyzed 8 weeks after BM transfer by determining the ratio of CD45.1 + to CD45.2 + immune subsets in blood by flow cytometry.
MCMV Plaque Assays
Livers (or salivary glands for MCMV viral stock titration) were homogenized 3.5 days post-MCMV infection and serially diluted samples were incubated on NIH 3T3 monolayer with rotation for 2hr at 37 C. Samples were removed and monolayers were overlayed with DMEM-Carboxymethylcellulose 5 days at 37 C. Cells were fixed with formaldehyde and stained with crystal violet for 5 minutes at room temperature and plaques were counted (Orange et al., 1995) . 
In vivo
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical parameters are described in figure legends. Student's t tests (two-tailed, unpaired, or where indicated paired), one-way Anova, two-way Anova, Mann-Whitney tests, and multiple comparisons were performed with GraphPad Prism 6.0 (GraphPad). Significance was defined as p % 0.05. In all figures, error bars indicate SEM.
